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ABSTRACT 
Background: Takotsubo syndrome (TTS), also recognized as “stress-induced 
cardiomyopathy (SIC)” and “broken heart syndrome”, is an acute cardiac failure 
syndrome characterized by transient regional ventricular akinesia or hypokinesia, 
and often presents similarly to acute myocardial infarction (AMI). In contrast to 
AMI, the characteristic regional myocardial akinesia in TTS does not involve a 
culprit coronary artery. Although the associated cardiac dysfunction is potentially 
reversible, TTS is no longer regarded as benign. Today we know that TTS can 
lead to deleterious complications including death. Because physical and/or 
emotional stress often precedes TTS, acute sympathetic stimulation is understood 
to play a central role in pathophysiology of TTS, but the detailed mechanisms are 
still unclear. There are no clinical randomized studies in patients with TTS. 
Therefore, we currently lack guidelines for treatment. 
Aims: The aims of this thesis were to study the reproducibility of our rat model, 
to unravel TTS pathophysiology and to explore possible prevention and treatment 
strategies in TTS. We aimed to investigate whether exogenous catecholamines 
can induce TTS-like cardiac dysfunction in rats. 
 Methods:  We used 10-week-old Sprague Dawley rats in these preclinical 
studies. We based this work on our experimental TTS rat model which is based on 
exogenous isoprenaline. We tested whether different catecholamines, given 
intraperitoneally in titrated doses, could induce TTS. We studied possible 
preventive roles of β-blockers, ivabradine, sacubitril/valsartan and 
cardiostimulants in our rat model. Blood pressure and heart rate were recorded via 
cannulation of right carotid artery. Small animal echocardiography was used to 
study cardiac morphology and function, and cardiac tissues were collected for 
histopathological studies. 
Results: In Study I, we reproduced our isoprenaline-based rat model of TTS and 
showed that exogenous catecholamines can induce different patterns of TTS, 
depending on the associated blood pressure rather than their adrenergic receptor 
affinities. In Study II, we observed that phosphodiesterase inhibitor milrinone can 
induce typical TTS. We demonstrated that pretreatment with either β-non-selective 
antagonist or β1-selective antagonist, but not β2-selective antagonist, can prevent 
isoprenaline-induced TTS. Cardiostimulants failed to prevent isoprenaline-induced 
apical TTS. In fact, pretreatment with levosimendan worsened the degree of left 
ventricular apical akinesia. In Study III, we showed that ivabradine as well as heart 
block could prevent isoprenaline-induced TTS. Finally, in Study IV, we showed 
that pretreatment with sacubitril/valsartan can reduce mortality and prevent 
isoprenaline-induced TTS. 
Conclusion: Our isoprenaline-based rat model of TTS is reproducible. 
Exogenous catecholamines can cause different variants of TTS depending on the 
associated haemodynamic profiles rather than catecholamine adrenergic receptor 
affinities. Hypotension and tachycardia precede isoprenaline-induced LV apical 
TTS in rats. Phenylephrine, ivabradine and β1-selective antagonists could prevent 
typical TTS. These drugs mitigate the unique isoprenaline-associated 
haemodynamic profile. Takotsubo syndrome should, therefore, be regarded as an 
acute sympathetic stimulation-induced haemo-neuro-cardiac syndrome rather 
than a cardiomyopathy per se. Inotrope and cardiostimulants such as milrinone 
and levosimendan can be deleterious in TTS. 
Key words: Takotsubo syndrome, milrinone, levosimendan, echocardiography, 
isoprenaline, sacubitril/valsartan, ivabradine, stress-induced cardiomyopathy. 

SAMMANFATTNING PÅ SVENSKA 
Takotsubo Syndrome (TTS) är akut hjärtsvikt sjukdom karakteriserad med akut 
potentiell reversible mykoardial akinesi, patienter med TTS presenteras oftast med 
symtom bild som liknar akut hjärt infarkt (AMI). TTS kan leda till allvarliga 
komplikationer som akut lungödem, synkope, arytmi, chock eller hjärtruptur. 
Mortalitet i TTS liknar detta i AMI. Patofysiologi i TTS är oklar, men stresshormoner 
och sympatisk stimulation tros spela stor roll. Det finns fortfarande inga 
randomiserade kliniska studier om TTS, varför vi saknar guidelines för behandling 
av patienter med TTS. Syftet med mitt doktorandprojekt är att studera om vi kan 
inducera TTS genom injicering av råttor med stresshormoner, kallas för 
catecholaminer. Vi syftade att studera patofysiologi av TTS från hemodynamisk 
effekter av catecholaminer på råttor och att utvärdera olika behandlingsalternativ. 
I Study I, visade vi att vi kan reproducera vår TTS råttamodell där isoprenaline 
injektion orsakar vänster kammaran apikalt akinesi. Vi visade också att olika 
catecholaminer kan leda till olika form av TTS baserat på associerat blodtryck. 
Manipulering av blodtryck medför omplacering av TTS akinesi position. Study II, 
visade vi att β-blockerande kan förebygga mot TTS i råttor. Hjärtstimulerande 
läkemedel, milrinone, kan orsaka TTS, precis som isoprenaline. Vi visade också 
att hjärtstimulerande mediciner försämrar isoprenaline inducerad TTS. I Study III 
och IV, vi visade pretreatment med ivabradine eller sacubitril/valsartan kan skydda 
mot utveckling av isoprenaline inducerad TTS i råttor. 
Sammanfattningsvis har vi visat att catecholaminer kan leda till TTS av olika form, 
β-blockerande, ivabradine samt sacubitril/valsartan kan skydda mot TTS. 
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ABBREVIATIONS 
ACS acute coronary syndrome 
ADR  adrenaline 
AMI acute myocardial infarction 
AVN atrioventricular node 
BP blood pressure 
BW body weight 
Cath catheterization  
CHB  complete heart block 
DOP  dopamine 
ECG electrocardiogram 
EKV electrocardiogram-gated kilohertz visualization technique 
ICI     selective β2 antagonist 
ISO     isoprenaline 
IVAB     ivabradine 
LA left atrium 
LEVO     levosimendan 
LV left ventricular/left ventricle 
LVAW  left ventricular anterior wall 
LVPW  left ventricular posterior wall 
MET      metoprolol      
MIL     milrinone 
NOR     noradrenaline 
PHE     phenylephrine 
PROP      propranolol 
SAC/VAL  sacubitril/valsartan  
SAN  sinoatrial node 
SIC     stress-induced cardiomyopathy 
2 
ST sympathetic tone 
TTS Takotsubo syndrome 
VAL  valsartan 
VC vasoconstriction 
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1. INTRODUCTION 
1.1 Takotsubo syndrome  
Takotsubo syndrome (TTS) is an increasingly recognized acute cardiac failure 
syndrome with a clinical presentation similar to that of 
acute myocardial infarction (AMI). Takotsubo 
syndrome is characterized by regional akinesia or 
hypokinesia of the myocardium, which, unlike in AMI, 
does not involve a culprit coronary artery.  
 
The syndrome is also known as “broken heart syndrome” or “stress-induced 
cardiomyopathy (SIC)” as the majority of TTS patients have preceding somatic 
and/or emotional stress. Typical TTS presents with left ventricular 1 apical akinesia 
and basal hyperkinesia (Fig. 1). However, atypical TTS patterns such as  basal2 3 
, global4, focal5,  LV mid- ventricular2, biventricular6 and even isolated right 
ventricle7 involvement have been reported6.
Takotsubo syndrome is no longer regarded as benign as was once believed. We 
now know that it can lead to lethal complications such as malignant arrhythmias, 
thromboembolic events including stroke, cardiac rupture and cardiogenic shock8 9. 
A recent study has shown that mortality in TTS is equivalent to that in AMI10. 
Nevertheless, cardiac dysfunction in TTS is characteristically reversible if the 
patient survives the acute phase. Despite some proposals11-13, there is still no 
consensus on TTS-specific diagnostic criteria and management. Hence, preclinical 
studies utilizing a well-established TTS animal model are needed to pave the way 
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for a better understanding of the otherwise still ambiguous pathophysiology and 
for exploring different possible treatment options. 
1.2 Epidemiology  
Takotsubo syndrome was first reported in six patients in 198514. The first to 
describe the condition, in 1990, was the team of  Dr. Hikaru Sato in Japan15. Since 
then, TTS has been increasingly reported worldwide11 16. Although elderly women 
are predominantly affected17, TTS can affect both genders of all ages18, even 
children19 20 and neonates21. The condition accounts for 1–2% of acute coronary 
syndrome (ACS) patients22 23. The prevalence of TTS appears to be 
underestimated as, with increasing awareness, TTS was reported to increase by 
20% in the period 2006–201224. The reported TTS recurrence rate ranges from 0% 
to 22%25. 
1.3 Morphological variants in Takotsubo syndrome 
Classically, typical TTS is characterized by extensive LV apical akinesia associated 
with LV basal hyperkinesia. Classically, atypical or reverse TTS is characterized 
by LV basal akinesia with preserved contraction at the LV apex. However, 
increasingly, different patterns of regional myocardial akinesia are being 
described23. Interestingly, the site of akinesia in TTS can change within the same 
admission26 27 and in recurrent TTS27-34. It can also change in rats, based on the 
associated blood pressure (BP), as we showed in Study I. 
In this thesis, the terms “typical” and “apical TTS” are interchangeably used to 
describe LV apical akinesia with a normally contracting base, while “atypical TTS” 
is used to refer to an akinetic LV base with a normally contracting apex. 
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1.4 Clinical presentation  
Takotsubo syndrome is an increasingly recognized acute cardiac syndrome. It is 
an important differential diagnosis in patients presenting with acute chest pain and 
acute heart failure. It often has a clinical picture similar to that of ACS. Typically, 
the patient is a postmenopausal woman presenting with acute anginal pain and/or 
dyspnoea. Preceding emotional and/ or physical stress may be present. Ischaemic 
electrocardiogram (ECG) changes, commonly pericordial T-wave inversion, are 
seen in most patients with TTS35 36 and biomarkers of myocardial ischaemia are 
seen in virtually all TTS cases18. Takotsubo syndrome can be diagnosed by 
echocardiography. As AMI and TTS are not mutually exclusive and can co-exist37, 
distinguishing between AMI and TTS requires echocardiography/ventriculography 
and coronary angiography. The akinesia in TTS is often circumferential and 
associated with absence of explanatory coronary culprit lesions on the 
angiogram38. Physical stress, acute psychiatric or neurological disease, elevated 
troponin and low ejection fraction are independent risk factors associated with poor 
outcome in TTS17. In-hospital mortality has been reported to be 20.9% and 2.6% 
in TTS following physical and emotional stress, respectively. 
 
1.5 Pathophysiology of Takotsubo syndrome – current hypothesis  
The pathophysiology of TTS is incompletely understood. Evidence suggests that 
sympathetic system stimulation plays a central role in TTS39. Patients with TTS 
have been shown to have elevated catecholamines40 41. Stress, sympathomimetic 
drugs42-45 and endogenous as well as exogenous catecholamines46-49 can all 
induce TTS.  
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Yet there is a knowledge gap regarding the causal relationship between 
sympathetic system stimulation and TTS50. The main postulations to elucidate this 
relationship are that excess adrenaline (ADR) changes the β2 adrenergic receptor 
response from stimulation to inhibition51, causing preferential LV apical akinesia as 
there are more β2 adrenergic receptors at the apex than in the rest of the LV; other 
postulations include coronary microvascular spasm; endothelial dysfunction; and 
local myocardial sympathetic stimulation52. These postulations are based on static 
anatomical distributions of myocardial vascular adrenergic nerves or β2 adrenergic 
receptors. The widely accepted theory is based on the fact that the LV apex is rich 
in β2 adrenergic receptors. Excessive ADR, by switching β2 adrenergic receptor 
response from stimulatory to inhibitory, causes typical TTS. 
However, the akinesia in TTS is neither confined to the LV nor LV apex. It is not 
necessarily static; in fact, it has been shown to be dynamic28-33 and in Study I, we 
found that the site of LV akinesia in catecholamine-induced TTS depends on the 
associated BP rather than the adrenergic receptor affinity.  
2. AIMS  
The general aims of this thesis were to unravel the pathophysiology behind TTS 
and to identify management options that could be beneficial for patients with TTS.   
The specific aims of each study in this thesis are given below: 
I: To establish the catecholamine causation for TTS by studying whether our 
isoprenaline based TTS rat model is reproducible and whether other 
catecholamines can induce TTS in rats. We also aimed to explore the 
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pathophysiology of TTS inferred from effects of these catecholamines on 
haemodynamic profiles, lipid metabolism and cardiac function parameters.  
II: To study the effects of pretreatment with cardiostimulants and β-blockers of 
different adrenergic receptor selectivity on development of LV apical akinesia in 
our ISO-based TTS rat model. 
III: To explore whether pure heart rate reduction, using ivabradine (IVAB) or heart 
block, could prevent ISO-induced, TTS-like cardiac dysfunction in rats. 
IV: To study the effects of pretreatment with sacubitril/valsartan (SAC/VAL) on 
development of ISO-induced TTS-like cardiac dysfunction in rats.          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
3. METHODS  
The methods used are detailed in the respective studies at the end of this thesis. 
Below is a brief account of these methods: 
3.1 Animals 
In all studies, 10-week-old Sprague Dawley rats were used. In Study I, II and IV, 
male rats were used, while female rats were used in Study III. Experiments from 
our reproducible rat model of TTS, which is based on male rats, showed less data 
variance and, hence, strong statistical power. However, because the majority of 
TTS patients are females, we used female rats in Study III.  
3.2 Vascular access and invasive haemodynamic recording 
We dissected free and cannulated right internal jugular vein and right common 
carotid artery for delivery of parenteral infusion and continuous recording of BP, 
respectively. Small animal ECG systems were used to monitor heart rate. We used 
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different approaches, detailed in each study, to measure and analyse heart rate 
and BP. 
3.3 Echocardiography 
We performed echocardiography on rats under general anaesthesia. Using ECG-
gated technique (EKV), cine loops were acquired in long-axis view to check for 
development of TTS-like akinesia and cardiac dysfunction. The degree of TTS-like 
akinesia was traced along the endocardial border and expressed as a percentage 
of LV endocardial length. Echo images were optimized by consistent positioning of 
the ultrasound probe after maintaining the LV long-axis view showing the aortic 
valve, mitral valve and maximal LV lumen area. 
4. RESULTS AND CONCLUSIONS 
Below are the main results of and conclusions drawn from each study. See the 
respective studies at the end of this thesis for detailed results and conclusions. 
4.1 Study I 
Different catecholamines induce different patterns of takotsubo-like cardiac dysfunction in 
an apparently afterload-dependent manner 
We have shown that catecholamines ISO, epinephrine, norepinephrine, 
phenylephrine 54 and dopamine (DOP) were all associated with development of 
SIC-like akinesia, or TTS-like cardiac dysfunction, in rats.  
With the exception of ISO, all tested catecholamines caused increased BP and 
were associated with atypical, SIC-like dysfunction (LV basal akinesia with 
preserved apical contractility). Isoprenaline lowered the BP and was associated 
 9 
 
with typical, SIC-like dysfunction (LV apical akinesia with preserved contractility at 
the LV base). 
Lowering the BP to below 120 mmHg by arterial vasodilators in hypertensive 
catecholamine groups resulted in changing the TTS phenotype from basal to 
typical apical akinesia. By contrast, maintaining the BP at above 120 mmHg by 
PHE in the ISO group attenuated the TTS-like apical dysfunction and did not result 
in LV basal dysfunction. 
We concluded that, in these catecholamine-based rat models of TTS-like cardiac 
dysfunction, low BP is associated with apical cardiac dysfunction while high BP is 
associated with LV basal cardiac dysfunction. We hypothesize that haemodynamic 
factors may be important in TTS pathogenesis and that TTS should be regarded 
as a cardio-circulatory syndrome rather than a mere cardiomyopathy. 
4.2 Study II 
Effects of pretreatment with cardiostimulants and beta-blockers on isoprenaline-induced 
takotsubo-like cardiac dysfunction in rats 
We showed that milrinone (MIL) can induce typical apical LV akinesia in a manner 
similar to ISO. Pretreatment with either propranolol (PROP) or metoprolol (MET), 
but not with ICI 118551, attenuated ISO-induced, SIC-like cardiac dysfunction in a 
dose-dependent manner. Pretreatment with levosimendan (LEVO) accentuated 
apical ballooning, while pretreatment with MIL did not affect the degree of akinesia. 
We concluded that Takotsubo-like cardiac dysfunction in rats can be induced by 
the phosphodiesterase inhibitor MIL. This conclusion challenges the notion that 
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catecholamine elevation precedes development of TTS. We provided 
experimental evidence for inotropes avoidance in managing patients with TTS. β1, 
rather than β2, adrenergic receptors may play a role in pathophysiology of TTS. 
4.3 Study III 
The role of heart rate in isoprenaline-induced takotsubo-like cardiac dysfunction in rats 
Similarly, induction of complete heart block (CHB) resulted in significant 
bradycardia and attenuated ISO-induced apical ballooning. We concluded that 
ISO-induced TTS-like cardiac dysfunction in rats can be prevented by mitigating 
ISO-induced tachycardia. 
4.4 Study IV 
Sacubitril/valsartan decreases mortality and attenuates development of apical akinesia in rat 
model of isoprenaline-induced takotsubo-like syndrome 
Compared with the control group, pretreatment with SAC/VAL resulted in less 
pronounced TTS-like cardiac dysfunction and lower mortality, while pretreatment 
with valsartan (VAL) alone did not achieve lowered cardiac dysfunction or 
mortality. Heart rate and BP were not significantly different between the groups.  
We concluded that pretreatment with SAC/VAL, but not with VAL, reduces 
mortality and attenuates ISO-induced apical akinesia in the rat model of TTS. 
Sacubitril/valsartan could be a potential treatment option in human patients with 
TTS. 
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5. DISCUSSION  
5.1 Takotsubo syndrome pathophysiology 
Despite numerous hypotheses, the precise pathophysiology of TTS is still 
unknown. Catecholamines as well as sympathomimetics can induce TTS42 46 and 
patients with TTS have been reported to have high catecholamines levels55 as well 
as sympathetic tone (ST)56. Therefore, sympathetic overstimulation and excess 
catecholamines are believed to play a causative role, but exact mechanisms 
remain speculative. The proposed mechanisms mainly include: 
Adrenaline-β2 adrenergic receptor switch theory  
Lyon et al hypothesize that excessive ADR, but not noradrenaline (NOR), causes 
β2-rich LV apex akinesia by switching pathways: mediating first the stimulatory 
β2–Gs protein pathway and then switching to the inhibitory β2–Gi protein 
pathway51. This theory might explain typical TTS, but is difficult to reconcile with 
atypical TTS that spares LV apex. Of note is that other catecholamines that do not 
even act via β2 can induce TTS46. 
Calcium overload theory 
Catecholamines at physiological levels increase cardiomyocyte–calcium cycling 
which enhances contractility. Calcium overload following release of excessive 
catecholamines that could jeopardize myocardial viability57 has been suggested to 
explain the akinesia of TTS53. 
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Influx of inflammatory cells and free radicals 
Influx of inflammatory cells and free radicals into myocardium has been observed 
in TTS58 59. However, it is unclear whether such influxes have a role in TTS 
pathophysiology or merely follow tissue injury. Adrenergic overstimulation could 
cause myocardial injury that causes inflammatory cells influx. 
Coronary macro/microvascular dysfunction 
Dote et al suggested coronary spasm to explain the occurrence of TTS after 
observing this lesion in two patients60; however, subsequent studies showed that 
the majority of TTS patients do not have coronary spasm61. The fact that dominant 
vasodilators, such as ADR and dobutamine, have been reported to cause TTS41 
argues against the coronary vasospasm hypothesis. Perfusion defects have been 
observed in patients with TTS. But these defects were reported in the aftermath of 
TTS62; therefore, it is not clear whether they are the cause or result of TTS. In our 
TTS rat model we reported normal perfusion at the akinesia sites63. 
Although sympathetic stimulation plays a central role in TTS pathophysiology, 
there remain knowledge gaps regarding the catecholamine/sympathetic 
stimulation–TTS mechanistic relationship. 
The findings of our experimental studies shed a light on the otherwise still unclear 
pathophysiology behind TTS64. There is a consensus that sympathetic stimulation 
plays a central role39. However, myocardial anatomical distribution of vessels, 
adrenergic receptors or nerves cannot explain the dynamic nature of TTS 
akinesia65.   
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5.2 Catecholamine-Takotsubosyndrome (TTS) causal relationship. The role 
of afterload in TTS pathophysiology 
In Study I we produced a rat model of TTS66 where a single bolus dose of 
intraperitoneal ISO 50 mg/kg body weight (BW) produced most of the 
morphological and clinical picture of typical TTS in humans66. Importantly, aside 
from ISO, we showed PHE, ADR, DOP and NOR to induce atypical, LV basal TTS. 
Isoprenaline is a synthetic, non-selective β-adrenergic receptor agonist. In addition 
to its direct positive inotropic and chronotropic effects, it causes peripheral 
vasodilation, hence hypotension via β2 adrenergic receptors67. By contrast, the 
other tested catecholamines induce vasoconstriction and hypertension via 
stimulation of their α-adrenergic receptor68. 
Contray to ISO, which causes hypotension and a typical form of TTS, the other 
catecholamines fundamentally induce hypertension and atypical TTS. Intriguingly, 
the associated LV basal TTS pattern switched to typical, or apical, TTS with 
interventions to keep BP low. On the other hand, normalizing the otherwise low BP 
abolished ISO-induced apical TTS (Fig. 2, Fig. 3). Such dynamic nature of the 
akinesia site is reported in patients with TTS28-31 69 70.  
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Based on our findings that exogenous catecholamines induced TTS, the form of 
which is dependent on whether the BP is high or low, we proposed this difference 
in BP to affect the distribution of LV regional wall tension that determines the TTS 
akinesia site.  
In the context of exogenous catecholamines, hypotension induces intense 
inotropic drive that may cause near obliteration of LV outflow during systole and 
preferentially increases regional wall tension at the LV apex. On the other hand, 
hypertension mitigates the intense inotropic drive, and leads to less myocardial 
contraction and a different wall stress distribution pattern. 
5.3 Our hypothesis  
We proposed that the regional mechanical overload plays a role in TTS 
pathophysiology (Fig. 4). Further, that cardiac cells in mechanically overloaded 
regions face excessive metabolic demands and a form of supply–demand 
mismatch. Takotsubo syndrome could essentially be protective against necrosis 
and akinetic cardiomyocytes could undergo protective metabolic shutdown for their 
survival. This may explain the high recovery rate seen in TTS. 
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5.4 Our hypothesis revisited 
Our hypothesis71 is based on exogenous catecholamine-induced haemodynamic 
effects and the impacts of these effects on the distribution of myocardial wall 
tension. 
5.5 The role of blood pressure in Takotsubo syndrome pathophysiology  
The pathophysiology of TTS could be multifactorial and complex72. But our 
consistent findings in Study I, that exogenous catecholamines induce typical LV 
apical or basal TTS depending on whether the associated BP is low or high, can 
be translated into haemodynamic-induced acute dysfunctional baroreflex input to 
the heart73. Catecholamines could cause TTS through an acute autonomic 
imbalance that interrupts normal sequential cardiac electromechanical synergy. 
5.6 The role of heart rate in Takotsubo syndrome pathophysiology  
In our rat model of TTS, the apparent LV outlet obstruction could be a result of 
ISO-induced unopposed sympathetic storm rather than a cause of LV apical 
akinesia. Normalizing BP, which could mean mitigating sympathetic 
overstimulation of cardiac conduction system, and, hence, less tachycardia, 
prevented ISO-induced apical TTS, as shown in Study I. Furthermore, in Study II, 
we found a strong positive association between heart rate and the extent of LV 
apical akinesia. We reported that β-blockers mitigate tachycardia and ISO-induced 
apical TTS. We also found that a high dose of LEVO exacerbated the ISO-induced 
TTS. Selective blockade of β1, but not β2, adrenoreceptors reduces the extent of 
akinesia. Together, these results indicate that excessive inotropic and chronotropic 
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stimulation, and β1 rather than β2 adrenoreceptors, play an important role in the 
pathophysiology of TTS. The next step was to study whether non-beta blocker 
bradycardia could prevent ISO-induced apical TTS in rats. To obtain pure heart 
rate reduction, we used IVAB and mechanical heart block. Consequently, in Study 
III we found IVAB as well as heart block to prevent ISO-induced apical TTS (Fig. 
5). 
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5.7 Sympathovagal imbalance and Takotsubo syndrome  
There is knowledge gap regarding what happens between acute sympathetic 
stimulation and development of different TTS variants. At the end of this thesis, we 
propose that sympathovagal interplay may have a role in TTS pathophysiology 
(Fig. 6). Briefly, vagal withdrawal induced by hypotension54 74 and ISO75-77 exposes 
the heart to unopposed, yet augmented sympathetic stimulation that could reverse 
the normal apex-to-base repolarization78, 79 and prolong the action potential more 
at the apex than at the base of the LV79. This could explain the LV basal 
electromechanical dominance over the apex, with ISO producing the apical variant 
of TTS. Atypical basal TTS, as seen in Study I, could be related to catecholamine-
induced exaggerated vagal response to sympathetic stimulus 80 81. Future studies 
are needed to explore the role of electromechanical dyssynchrony in 
pathophysiology of TTS.  
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5.8 Typical Takotsubo syndrome in the absence of elevated catecholamines 
In Study II, we found that MIL, a phosphodiesterase inhibitor that does not act 
directly via adrenoceptors, induces typical TTS, similar to ISO, in rats. This finding 
suggests that TTS can occur in the absence of elevated catecholamines and it 
challenges the concept that high levels of circulating catecholamines or direct 
excessive stimulation of myocardial adrenergic receptors are necessary for the 
development of TTS. Like ISO75-77, 82 83, MIL accelerates cardiac conduction84-86 
and induces vasodilation86-89, which could cause vagal withdrawal54 74. 
Hypotension and tachycardia are commonly associated with apical TTS induced 
by ISO and MIL. 
6. TREATMENT OF PATIENTS WITH TAKOTSUBO SYNDROME
There have been no prospective randomized clinical trials in patients with TTS. 
Therefore, treatment guidelines for TTS are currently lacking. In TTS patients, 
beta-blockers mitigate the severity of recurrent TTS90 91. However, reports about 
treatment with beta-blockers are contradictory. Some recommended inclusion of 
beta-blockers in the TTS treatment protocol1, while others reported that beta-
blockers have no benefit regarding short7 and long-term mortality7 in TTS. 
6.1 Prevention of Takotsubo syndrome 
The role of beta-blockers in TTS management is therefore controversial91. Our 
findings in Study II indicate that cardio-selective beta-blockers could prevent 
apical TTS. Pretreatment with MET led to a dose-dependent reduction in TTS 
akinesia and mortality in rats. Similar effects of MET on TTS were reported in 
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monkeys92. Beta-blockers were reported to reduce severity in recurrent TTS93. We 
found MET 50 mg/kg BW to prevent ISO-induced apical TTS. 
In Study III, we showed a beneficial role of pretreatment with IVAB in prevention 
of ISO-induced TTS in rats. These findings are in accordance with reports showing 
that IVAB plays a role in treatment of TTS patients94-96.  
6.2 Acute management of Takotsubo syndrome 
Ideally, patients with TTS are managed at a cardiology unit with a catheterization 
17 lab and imaging facilities. Currently, there are no randomized clinical trials (RCT) 
in TTS that we can base our recommendations on. First, do no harm (Primum nil 
nocere) should be recommended as TTS is largely regarded as self-healing 
syndrome. 
Cautious use of beta-blockers seems reasonable97 as catecholamines and 
sympathetic stimulation play a central role in TTS pathophysiology. In Study II, we 
showed that MET and PROP can prevent ISO-induced apical TTS in rats. 
We also showed that a high dose of LEVO worsened ISO-induced TTS and that 
selective blockade of β1, but not β2, adrenoreceptors reduces the extent of 
akinesia. These results provide experimental evidence  for avoidance of positive 
inotrope in treatment of TTS98 and that β1, rather than β2, adrenoreceptors play an 
important role in the pathophysiology of TTS. 
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7. CONCLUDING REMARKS AND FUTURE PRESPECTIVES 
We reproduced our ISO injection-based rat model that contains most 
morphological and clinical features of TTS. We provided experimental evidence 
for a catecholamine–TTS causation relationship by showing that TTS can be 
induced by exogenous catecholamines. 
The site of akinesia in catecholamine-induced TTS is determined by afterload. In 
this context, low afterload leading to an unopposed sympathetic storm, and high 
afterload leading to acute augmented vagal hypertonia, both of which could 
interrupt normal LV electromechanical synchrony. LV base electrical dominance 
could precede its mechanical dominance over the apex in ISO-induced apical TTS. 
Interruption of sympathetic overstimulation at the sinoatrial node (SAN) or 
atrioventricular node (AVN) by IVAB or CHB, as well as pretreatment with MET, 
prevented ISO-induced typical TTS in rats. These findings highlight the role of ISO-
induced augmented unopposed overstimulation of the sympathetic cardiac 
conduction system in the pathophysiology of apical TTS. Future studies need to 
investigate whether LV electromechanical dyssynchrony precedes development of 
akinesia in TTS. 
β-blockers and IVAB could have a role in prevention and treatment of TTS. 
Randomized controlled studies are needed to establish TTS treatment guidelines. 
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